<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100279'>Ulcerative colitis</z:hpo> (UC) is a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> of the colon that typically manifests as <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, and bloody stool </plain></SENT>
<SENT sid="1" pm="."><plain>Complications, such as <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and extraintestinal manifestations, may also develop </plain></SENT>
<SENT sid="2" pm="."><plain>The goals of management are to induce and maintain clinical remission and to screen for complications of this disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6775">Mesalamine</z:chebi> is a <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC </plain></SENT>
<SENT sid="4" pm="."><plain>For patients who are refractory to <z:chebi fb="0" ids="6775">mesalamine</z:chebi> or have more severe disease, steroids, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>/<z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, or infliximab may be used, induce and/or maintain remission </plain></SENT>
<SENT sid="5" pm="."><plain>The various formulations of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6775">Mesalamine</z:chebi> with Multi-Matrix System(®) (<z:chebi fb="0" ids="53464">MMX</z:chebi>) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> used for the treatment of UC (Lialda(®) or Mezavant(®), Shire Pharmaceuticals Inc, Wayne, PA) </plain></SENT>
<SENT sid="7" pm="."><plain>In clinical studies, <z:chebi fb="0" ids="53464">MMX</z:chebi> <z:chebi fb="0" ids="6775">mesalamine</z:chebi> (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC </plain></SENT>
<SENT sid="8" pm="."><plain>The overall safety profile of <z:chebi fb="0" ids="53464">MMX</z:chebi> <z:chebi fb="0" ids="6775">mesalamine</z:chebi> is similar to other oral <z:chebi fb="0" ids="6775">mesalamine</z:chebi> formulations </plain></SENT>
<SENT sid="9" pm="."><plain>The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to <z:chebi fb="0" ids="6775">mesalamine</z:chebi> therapy </plain></SENT>
</text></document>